Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes
NCT05700877 on ClinicalTrials.gov · last registry update 2025-02-06
An unusually large phase 4: 7,300 participants, more than double the 72 typical for the stage. Due to report 1 January 2029, alongside 8 other tracked readouts that quarter. Primary outcome, as filed: Rates of a composite cardiovascular endpoint. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 12 January 2023 — 3 years so far. semaglutide is already approved in the US for cardiovascular disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Per Løgstrup Poulsen
- Sponsor type
- Other
- Enrollment
- 7,300
- Started
- 2023-01-12
- Primary completion
- 2029-01-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Rates of a composite cardiovascular endpoint
Conditions studied
Type 2 Diabetes · Cardiovascular Diseases
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.